This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. To explore if oral administration of pioglitazone can be used as neuroprotective therapy in Parkinson's disease. The identification of therapies aimed to slow or stop the progressive dopaminergic neuronal loss has become a priority for Parkinson s disease. Pioglitazone is an antidiabetic therapy that has been found to have anti- inflammatory and anti-oxidant properties. Pioglitazone administration was able to protect against the induction of a parkinsonian syndrome in mice. As pioglitazone is currently FDA approved, the finding of positive results of neuroprotection in a non human primate model of PD will move forward the application towards clinical trials. Research use WNPRC Animal Services.
Showing the most recent 10 out of 528 publications